글로벌 글리코믹스 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

글리코믹스 시장 분석

글로벌 글리코믹스 시장은 기술의 발전과 약물 개발, 진단 및 개인 맞춤 의학 분야의 응용 분야 증가로 인해 상당한 성장을 경험하고 있습니다. 글리칸 구조와 생물학적 과정에서의 역할을 이해하는 것은 특히 암 연구, 면역학 및 감염성 질환과 같은 분야에서 중요해졌습니다. 이러한 지식의 확장은 탄수화물 기반 치료제의 혁신을 주도하고 있으며, 이는 의료 결과를 변화시킬 준비가 되어 있습니다. 그러나 시장은 높은 연구 비용, 복잡한 규제 환경 및 전문 지식의 필요성을 포함한 과제에 직면해 있습니다. 이러한 장애물에도 불구하고 글리코믹스 분야는 진단 및 치료 옵션의 발전에 유망한 기회를 제공하여 미래 연구 및 투자에 중요한 분야가 되었습니다. 연구자와 회사가 글리칸과 생물학적 기능 간의 복잡한 관계를 계속 탐구함에 따라 글리코믹스 시장은 차세대 치료법 개발과 환자 치료 개선에 중요한 역할을 할 것입니다.

글리코믹스 시장 규모

글로벌 글리코믹스 시장 규모는 2023년에 62억 7천만 달러로 평가되었으며, 2031년까지 182억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 14.25%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

글리코믹스 시장 동향

“ 개인화된 의학에 대한 집중 증가”

글리코믹스 시장은 분석 기술의 발전과 다양한 생물학적 과정에서 글리칸의 역할에 대한 이해 증가에 힘입어 상당한 성장을 경험하고 있습니다. 주목할 만한 추세 중 하나는 글리코생물학 연구의 효율성을 향상시키는 고처리량 글리칸 분석 방법의 채택 증가입니다. 예를 들어, Agilent Technologies와 같은 회사는 신속한 글리칸 프로파일링을 위한 혁신적인 도구를 개발하여 연구자들이 복잡한 탄수화물 구조를 보다 효율적으로 분석할 수 있도록 합니다. 이러한 추세는 글리코믹스가 질병 메커니즘을 이해하고 잠재적인 치료 표적을 식별하는 데 중요한 역할을 하는 진단 및 약물 개발 분야에서 특히 관련이 있습니다. 제약 및 생명공학 회사가 글리코믹스 연구에 점점 더 많이 투자함에 따라 특수 기기 및 시약에 대한 수요가 증가할 것으로 예상됩니다. 이러한 성장은 정밀 의학을 발전시키는 데 있어 글리코믹스의 중요성을 강조 하고 표적 치료법 개발을 용이하게 함으로써 종양학 및 면역학과 같은 분야에 혁명을 일으킬 수 있는 잠재력을 강조합니다.

보고서 범위 및 글리코믹스 시장 세분화  

Glycomics Market Definition

Glycomics is the comprehensive study of glycans, which are complex carbohydrates that play essential roles in various biological processes, including cell signaling, immune response, and disease progression. This field encompasses the analysis of glycan structures, functions, and interactions within biological systems. Glycomics is pivotal in advancing drug development, diagnostics, and personalized medicine by leveraging the unique glycan profiles associated with specific diseases.

Glycomics Market Dynamics

Drivers

• Increasing Incidence of Chronic Diseases

The rising incidence of chronic diseases is a significant driver of the glycomics market, as the World Health Organization (WHO) estimates that chronic diseases account for approximately 71% of all deaths globally, with cancer, diabetes, and cardiovascular diseases being the leading contributors. For instance, the International Diabetes Federation reports that approximately 500 million adults were living with diabetes in 2021, a figure projected to rise to around 650 million by 2030. This surge necessitates advancements in personalized medicine and diagnostics tailored to individual patient profiles, thereby intensifying interest in glycomics research. Glycans play a crucial role in disease processes, influencing cellular interactions, immune responses, and disease progression. As researchers explore glycan-based biomarkers for early diagnosis and treatment efficacy, the demand for glycomics tools and technologies is expected to grow significantly, thereby positioning the glycomics market as a pivotal sector in combating chronic diseases.

• Growing Investment in Research and Development (R&D)

Growing investment in research and development (R&D) is a critical driver of the glycomics market, as both public and private sectors increasingly allocate resources toward glycomics research initiatives. In 2019, global investment in R&D reached approximately USD 2.4 trillion, with significant portions directed toward biomedicine and biotechnology. For instance, the National Institutes of Health (NIH) in the U.S. announced an investment of USD 45 billion in research funding for the fiscal year 2022, which includes funding for glycomics-related studies aimed at understanding the roles of glycans in various diseases. This robust funding environment fosters the development of innovative therapeutic approaches and diagnostic tools, enhancing our understanding of disease mechanisms and enabling the discovery of glycan-based biomarkers. As a result, the emphasis on R&D promotes advancements in glycomics technologies and drives the overall growth of the glycomics market as new applications and products emerge from this research.

Opportunities

• Increasing Advancements in Glycomics Technologies

Advancements in glycomics technologies present a significant market opportunity, as innovations such as mass spectrometry, high-performance liquid chromatography (HPLC), and next-generation sequencing (NGS) have revolutionized the analysis of glycans and their biological roles. For instance, mass spectrometry has become a powerful tool for characterizing glycans due to its sensitivity and ability to analyze complex mixtures, allowing researchers to identify glycan structures in various biological samples accurately. These technological advancements improve the efficiency and accuracy of glycan analysis and drive the development of new applications in drug discovery, personalized medicine, and disease diagnostics. As the demand for precise glycan analysis continues to grow, the glycomics market is poised for substantial growth, fueled by ongoing innovations in glycomics technologies.

• Emerging Applications in Drug Development

Emerging applications in drug development represent a significant market opportunity for glycomics, as this field plays a crucial role in the design and production of biopharmaceuticals and vaccines. Glycans are essential for the efficacy and safety of many therapeutic proteins, influencing their stability, immunogenicity, and bioactivity. For instance, the development of the COVID-19 mRNA vaccines, such as those by Pfizer-BioNTech and Moderna, highlighted the importance of glycan structures in vaccine formulation, ensuring optimal immune responses. As the pharmaceutical and biotechnology industries increasingly recognize the significance of glycomics in developing new therapeutics, the demand for glycan analysis tools and technologies is expected to grow, driving the glycomics market forward.

Restraints/Challenges

• High Costs Associated with Glycomics Technologies

High costs associated with glycomics technologies pose a significant challenge to the market, as advanced tools such as mass spectrometry (MS) and high-performance liquid chromatography (HPLC) can be prohibitively expensive to acquire and maintain. For instance, a high-end mass spectrometer can cost upto several thousand dollars with additional expenses for maintenance, reagents, and specialized personnel. This financial barrier restricts access for smaller laboratories and academic institutions, which may lack the necessary funding to invest in such sophisticated equipment. Consequently, this limitation can slow the pace of glycomics research and innovation, hindering the development of glycan-based therapeutics and diagnostics. As a result, the overall growth of the glycomics market may be constrained, as fewer research entities can participate in cutting-edge studies and advancements.

• Complex Regulatory Frameworks

Regulatory challenges present a significant hurdle for the glycomics market, as products developed within this field, particularly biopharmaceuticals and diagnostics, must adhere to stringent scrutiny by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies require comprehensive data on safety, efficacy, and manufacturing processes, which can lead to lengthy approval timelines. Such complexity can delay the commercialization of glycan-based therapeutics and diagnostics, discouraging investment in glycomics research and development. Consequently, the uncertainty surrounding regulatory compliance may limit the market's growth potential as companies face significant hurdles in bringing innovative products to market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Glycomics Market Scope

The market is segmented on the basis of product, application, and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Enzymes
  • Glycosidases
  • Neuraminidases
  • Glycosyltransferases
  • Sialyltransferases
  • Others
• Instruments
  • Mass Spectrometers
  • HPLC
  • MALDI-TOF
  • Array Systems
  • Others
• Kits
  • Glycan Labeling Kits
  • Glycan Purification Kits
  • Glycan Release Kits
  • Others
• Reagents
  • Glycoproteins
  • Monosaccharides
  • Oligosaccharides
  • Others

Application

• Diagnostics
• Drug Discovery & Development
• Oncology
• Immunology
• Other Applications

End User

• Academic Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

Glycomics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, application, and end users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the glycomics market, driven by a strong presence of major pharmaceutical and biopharmaceutical companies, which fuels significant research and development activity. The region benefits from easy access to advanced glycomics products and technologies, supported by a robust healthcare infrastructure. Additionally, North America’s established network of research institutions and healthcare facilities contributes to high demand and adoption of glycomics applications across diagnostics and therapeutic areas.

The Asia-Pacific region is anticipated to experience substantial growth in the glycomics market from 2024 to 2031, largely due to its rapidly advancing pharmaceutical and biopharmaceutical sectors. Increasing investment in drug and biologics development, coupled with expanded production capabilities, supports this upward trend. Additionally, Asia-Pacific’s growing focus on innovation and expanding infrastructure for biotechnological research strengthens its role in the global glycomics market. This progress is further fueled by rising demand for advanced healthcare solutions across the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Glycomics Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 글리코믹스 시장 리더는 다음과 같습니다.

• 머크 KGaA(독일)
• 시마즈 주식회사(일본)
• 브루커(독일)
• 워터스 코퍼레이션(미국)
• Thermo Fisher Scientific Inc. (미국)
• Agilent Technologies, Inc. (미국)
• 뉴잉글랜드 바이오랩스(미국)
• 아스파리아 글리코믹스(캐나다)
• 벡터 연구소(미국)
• 베스 이스라엘 디코네스 의료 센터(미국)
• 캐나다 글리코믹스 네트워크(GLYCONET)(캐나다)
• 조지아 대학교, 아테네(미국)
• GlySign(네덜란드)
• 글리코디스플레이(독일)
• 레이바이오텍 주식회사(미국)
• 글리코디라이트(미국)
• LABORATORIOS FARMACEUTICOS ROVI SA(스페인)
• 글리코 익스프레션 테크놀로지스(미국)

글리코믹스 시장의 최신 동향

• 2023년 6월, Agilent Technologies Inc.는 다양한 시약 분주 및 플레이트 세척 기능을 제공하는 소형 기기인 Agilent BioTek 406 FX 세척기 디스펜서를 출시했습니다. 자동화 시스템에 통합하거나 단독 벤치탑 사용을 위해 설계된 BioTek 406 FX는 액체 처리 기능을 향상시킵니다.
• 2023년 3월, Waters Corporation은 일반적인 실험실 오류를 최대 40%까지 줄이도록 설계된 Next-Generation Alliance iS HPLC 시스템을 출시했습니다. 이 시스템은 실험실이 운영 위험을 관리하고, 중단을 최소화하며, 생산성을 높이는 데 도움이 됩니다.
• 2022년 9월, Thermo Fisher Scientific Inc.는 효율적인 대규모 세포 배양 수확을 위해 설계된 DynaSpin™ 일회용 원심분리 시스템을 공개했습니다. 이 시스템은 일회용 생물 응용 프로그램 내에서 세포 배양 분리 프로세스를 간소화하고 최적화합니다.
• 2022년 4월, 미국에 본사를 둔 Bruker Corporation은 다양한 응용 분야에서 DART 질량 분석기의 사용을 확대하기 위해 IonSense를 인수했습니다.
• 2021년 4월, GlycoNet(캐나다)은 BridgeBio Pharma Inc.(미국)와 협력하여 유전적 질환 치료제를 개발하는 것을 목표로 하는 당생물학 연구를 실시했습니다.

SKU-43652